Update on the efficacy of statin treatment in acute coronary syndromes

  title={Update on the efficacy of statin treatment in acute coronary syndromes},
  author={Gian Marco Rosa and Federico Carbone and Antonello Parodi and Elena Augusta Massimelli and Claudio Brunelli and François Mach and Nicolas Vuilleumier and Fabrizio Montecucco},
  journal={European Journal of Clinical Investigation},
  pages={501 - 515}
The natural history of atherosclerosis might involve coronary plaque rupture/erosion, thrombus formation and vessel lumen occlusion, clinically recognized as acute coronary syndrome (ACS). International guidelines strongly recommend early statin administration in patients admitted for ACS. In addition to lowering circulating levels of low‐density lipoprotein cholesterol (LDL‐c), statin treatment was shown to promote plaque stabilization or regression in several ways, including reduction in… 
Statin Induced Dysuria- A Case Report
In the present case after re-challenge with similar group of drug patient again developed the symptoms and underlying hyperlipidemia was effectively controlled with Fenofibrates.
This review aims to provide an overview of the landscape of lipidlowering therapy for the purpose of secondary prevention by summarising recommendations derived from contemporary guidelines and highlighting the rationale and evidence behind the three main lipid-lowering therapies, namely statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Acute Myocardial Infarction Occurring at a Preexisting Intermediate Coronary Artery Stenosis
Reports of acute myocardial infarction occurring at a preexisting intermediate coronary stenosis based on invasive coronary angiography performed 10 days before the event are reported.
PCSK9 inhibitors for treating hypercholesterolemia
The purpose of this narrative review is to summarize the current knowledge of PCSK9-i, with particular regard to pharmacodynamic, pharmacokinetic, and clinical data on evolocumab and alirocumab.
Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome
  • M. SobhyAdel El Etriby A. Gitt
  • Medicine
    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
  • 2018
A Review on Synthesis and Applications of Statin Family Drugs as a New Generations of Anti-Blood Medicines
This work studies the mechanism of the use of statin family drugs and atorvastatin to determine the clinical requirements for improving the dermatology and the statins.


Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study
Analysis of data from a large, international observational study of acute coronary syndromes identified associations between statin use before and during acute coronary events and favorable outcomes, and examined the effect of early in-hospital statin therapy on important hospital outcomes, including death or the development of recurrent MI or stroke.
Statins in acute coronary syndromes: do the guideline recommendations match the evidence?
Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes
Statin pretreatment in patients with acute coronary syndromes is associated with improved clinical outcome, however, discontinuation of statin therapy after onset of symptoms completely abrogates this beneficial effect.
Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin.
  • T. ToiI. Taguchi N. Kaneko
  • Medicine, Biology
    Circulation journal : official journal of the Japanese Circulation Society
  • 2009
Fibrofatty composition and plaque volume decreased significantly following treatment with pitavastatin, which suggests that pitavASTatin might have a higher affinity for fibrofat compared with atorvastatin.
Impact of statin therapy on coronary intervention for non-ST elevation acute coronary syndrome with decreased low-density lipoprotein cholesterol.
Statin treatment before PCI in patients with non-ST elevation ACS demonstrated beneficial effects such as less myocardial damage, even though both groups presented with low LDL cholesterol levels, however, no significant effect on MACE was seen at 6 months after PCI.
Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study
Early aggressive lipid-lowering therapy by atorvastatin for 6 months significantly reduced the plaque volume in patients with ACS, and Percent change in plaque volume showed a significant positive correlation with percent LDL-C reduction, even in Patients with low baseline cholesterol.
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Administration of high-dose statin in NSTE ACS patients before PCI was associated with significant reduction of MACE in long-term follow-up, and was observed despite the same therapy given after PCI.